Introduction {#s1}
============

Acetaminophen (APAP) is a commonly used analgesic and antipyretic drug that is found in a number of combined prescriptions, including Tylenol with codeine and Hycotab ([@B7]). Although its effectiveness and safety were confirmed at recommended doses, the APAP overdose causes hepatotoxicity that leads to acute liver failure (ALF) ([@B14]). According to the ALF Study Group in the United States, APAP-associated toxicity contributes to approximately 46% of all cases of ALF in adults, which far exceeds idiosyncratic drug-induced liver injury (DILI) by more than fourfolds ([@B68]; [@B59]).

Accumulating evidence has highlighted that APAP-induced oxidative stress and mitochondrial dysfunction are the fundamental factors in the pathogenesis of APAP-associated liver injury (ALI); thus, N-acetyl cysteine (NAC), a scavenger of reactive oxygen species (ROS), is considered a standard therapeutic option for APAP overdose ([@B50]). However, due to the narrow therapeutic window, severe adverse effects, and rapid disease progression, the therapeutic efficacy of NAC is still limited ([@B27]). For patients at the advanced stage, liver transplantation is the only way to improve survival outcomes ([@B19]). Therefore, new treatments that are superior to NAC in terms of therapeutic efficacy and safety are required in clinical practice.

Recently, herbal medicine was found to be a promising therapeutic approach for ALI. Several herbal components were reported to have the same therapeutic effect as NAC ([@B16]; [@B65]; [@B90]). In a previous study, the effectiveness of the treatment was significantly noticed when it was administered after APAP, but not as a pretreatment. These underlying limitations regarding the applicability and effectiveness of herbal therapy have been modified and improved in recent years by direct application in an APAP overdose setting. In this review, we highlighted recent advances and new findings regarding the impact, effectiveness, and underlying mechanisms of herbal therapies in ALI.

Underlying Mechanisms of APAP and ALI {#s1_1}
-------------------------------------

The majority of APAP is conjugated with glucuronic acid and then excreted through the kidney when consumed at therapeutic doses. The remnants of the dose form reactive metabolites (N-acetyl-p-benzoquinone imine; NAPQI) by cytochrome P450 enzymes ([@B62]). Although the reactiveness of NAPQI is high, it is barely harmful at the therapeutic dose because of its abundant glutathione storage and excretion through bile. In contrast, an overdose of APAP causes hepatotoxicity by saturating the sulfation pathway and generating NAPQI that leads to a robust reaction between NAPQI and hepatic glutathione stores, which subsequently depletes glutathione ([@B100]).

Currently, APAP protein adduct formation and release into the circulation is being utilized as a biomarker for APAP overdose ([@B22]). However, these molecules are also identified in the majority of subjects taking a therapeutic dose of APAP, and protein-derived APAP-cysteine is detectable after supratherapeutic consumption of APAP without hepatotoxicity ([@B67]). Recently, [@B74] differentiated ALI from the others using APAP protein adducts by developing an immunoassay that rapidly measures APAP protein adducts to identify ALF. Therefore, considering the presence of APAP protein adducts at the therapeutic dose of APAP, formation of protein adducts on mitochondrial proteins rather than the overall formation of protein adducts may be the reason for cellular toxicity, which has been considered a key factor for necrotic cell death in previous years ([@B51]; [@B48]).

Depleted glutathione by NAPQI leads to increased H~2~O~2~ release that oxidizes thioredoxin and induces the disassociation of thioredoxin from apoptosis signalling-regulating kinase 1 (ASK-1), triggering self-activation of ASK-1, which phosphorylates mitogen-activated protein kinase kinase 4/7 and activates c-Jun N-terminal kinase (JNK) ([@B46]; [@B66]). Activated JNK contributes to the dysfunction of the electron transport chain and increased ROS. In addition, sustained JNK activation was amplifies mitochondrial ROS and forms a self-sustaining activation loop ([@B98]). Furthermore, p-JNK leads to the activation of Bax and translocation to mitochondria to trigger the mitochondrial permeability transition (MPT) pore formation, along with collapsed ATP depletion and membrane potential, eventually causing DNA fragmentation and necrosis ([@B12]; [@B53]). In recent years, [@B54] demonstrated that metformin, a first-line drug for treatment of type 2 diabetes mellitus, has therapeutic effects against ALI by inhibiting p-JNK *via* upregulation of Gadd45β. However, a follow-up study showed that protective effect of metformin treatment in APAP-associated hepatotoxicity was independent of JNK ([@B28]). This effect may be associated with other factors, such as the inhibition of ROS production. Therefore, further confirmation of the underlying mechanisms of metformin against APAP-associated hepatotoxicity is necessary. Apart from metformin, p53 (a tumour suppressor protein) is activated due to oxidative stress in ALI, and protective during liver injury *via* inhibition of JNK, but also delays liver regeneration ([@B49]; [@B13]). Therefore, p53 seems not an ideal target for ALI considering its double-sided role in ALI pathogenesis.

Moreover, many other signalling pathways are promoted in response to the oxidative stress in APAP overdose. Nuclear factor erythroid 2-related factor 2 (Nrf2) is notably representative and is activated by NAPQI-induced redox status changes. Nrf2 was found to participate in transcriptional activation of antioxidant enzymes that act as a cell defensive system to detoxify NAPQI ([@B41]). In addition to activation by NAPQI, the Nrf2 signalling pathway is also regulated by protein tyrosine phosphatase 1B (PTP1B) and M1 muscarinic receptors (M1Rs) ([@B63]; [@B92]). APAP-associated hepatotoxicity is ameliorated by promoting the Nrf2 system in mice without PTP1B or M1R, indicating that PTP1B and/or M1R may be promising therapeutic targets in ALI. Considering the positive impact of Nrf2 in ameliorating oxidative stress, a number of bioactive components that exert protective effect against APAP-associated hepatotoxicity have been identified and reported, including caffeic acid that activates the Keap1-Nrf2 antioxidant defense system ([@B69]), carnosic acid that promotes nuclear translocation of Nrf2 ([@B44]), and esculentoside A that activates Nrf2 *via* AMP-activated kinase/Akt/glycogen synthase kinase 3 pathway ([@B95]). These studies reveal that pretreatment with the Nrf2-activating natural products prevents against ALI in APAP overdose. Overall, glutathione depletion, oxidative stress, and mitochondrial damage are the critical underlying mechanisms of ALI ([**Figure 1**](#f1){ref-type="fig"}).

![The underlying mechanisms of acetaminophen (APAP) to trigger associated liver injury (ALI). N-acetyl-p-benzoquinone imine generation by APAP overdose leads to depletion of glutathione, giving rise to mitochondrial oxidative stress and damage. It induces ATP depletion and the opening of the mitochondria permeability transition pore that contributes to the mitochondrial protein translocation, resulting in DNA fragmentation and subsequent necrosis. Reactive oxygen species (ROS) caused by N-acetyl-p-benzoquinone imine activates c-Jun N-terminal kinase and the sustained activation triggers mitochondrial ROS, and form a self-sustaining activation loop. Among the processes, autophagy alleviates liver injury by removing damaged mitochondria and detrimental APAP adducts.](fphar-11-00313-g001){#f1}

### Cytochrome P450-Mediated Metabolic Activation {#s1_1_1}

APAP metabolic activation is mainly catalyzed by the cytochrome P450 enzyme and the reactive metabolite associated with hepatotoxicity is commonly considered to be NAPQI ([@B21]). APAP overdose results in excess NAPQI formation that depletes glutathione levels and binds to proteins. A previous study confirmed increased turnover of glutathione after increasing APAP dose ([@B51]). Moreover, APAP-protein adducts can be measured in patients with APAP overdose ([@B22]). In addition, cysteine residues are the main targets for covalent alteration by the reactive intermediate of APAP ([@B84]).

Both alcohol and isoniazid induce CYP2E1 and affect APAP-induced ALI by increasing NAPQI, the hepatotoxic metabolite of APAP, indicating that CYP2E1 may be the major P450 contributing to conversion of APAP to NAPQI ([@B109]; [@B89]). Accordingly, less susceptibility of alcohol and isoniazid was observed in CYP2E1-knockout mice in an ALI setting ([@B58]). Apart from CYP2E1, CYP1A2, 2D6, and 3A4 have also been found to activate APAP in various models ([@B71]; [@B88]; [@B24]). Beta-catenin-deficient mice have been reported to show elimination of Cyp2e1 and 1a2 proteins, which are associated with resistance against APAP hepatotoxicity ([@B78]). Moreover, Cyp2e1-/- mice showed resistance to the APAP high dose-associated hepatotoxicity, whereas human CYP2E1 transgenic mice were susceptible, suggesting that CYP2E1 is the major P450 enzyme participating in APAP activation ([@B17]). Furthermore, APAP-protein adducts were detected after APAP treatment in human HepaRG cells that express low CYP2E1 levels ([@B9]). Therefore, CYP2E1 is the primary enzyme contributing to the conversion of APAP to its reactive intermediate along with other P450s, such as CYP1A2 and CYP3A4. At normal therapeutic dose, APAP is mainly metabolized *via* O-glucuronidation (50%--70%) and O-sulfation (approximately 25%) pathways and forms the corresponding conjugates that can be easily excreted by the kidney. Moreover, a minor proportion of this agent can be metabolized within the liver by the cytochrome P450 enzymes (primarily by CYP2E1) to NAPQI, which is detoxified by conjugation and excreted in the glutathione or NAC forms ([**Figure 2**](#f2){ref-type="fig"}). However, when the drug is taken in an overdose, the Uridine diphosphate-glucuronosyltransferases (UGTs) and sulfotransferases (SULTs) in the human liver that participate in APAP detoxification become saturated, and a considerable proportion of this drug is activated by human CYPs (primarily CYP2E1).

![The metabolic pathways of acetaminophen (APAP) in the human body. The major proportion of APAP is mainly metabolized to APAP-sulfate and -glucuronide, and the minor proportion is metabolized by CYP2E1 to NAPQI, which is subsequently metabolized to APAP-glutathione and -NAC.](fphar-11-00313-g002){#f2}

For the treatment of AALI (APAP-associated ALI), only NAC has been used as a classic therapy for APAP-associated hepatotoxicity induced by NAPQI. In recent years, cimetidine has been used to reduce toxic metabolites by inhibiting cytochrome p450; thus, some researchers have suggested using cimetidine as a complementary treatment for AALI ([@B6]). In addition, cimetidine is an available drug and its side effects could be found at very high doses ([@B99]). However, a double-blinded clinical trial involving 105 patients suspected of APAP toxicity who require medical treatment from Iran. Comparing the therapeutic efficacy of NAC or combination of NAC and cimetidine in patients with acute AALI, no significant improvement was found in hepatoprotective activities between intravenous administration of cimetidine (300 mg per 6 h) and the sole NAC treatment ([@B30]). However, the impact of cimetidine for prevention of ALI in individuals using APAP remains to be confirmed in the future.

APAP-Associated Idiosyncratic DILI {#s1_2}
----------------------------------

Both APAP-associated intrinsic and idiosyncratic DILI are defined by ALT elevation (≥5 × the upper limits of normal, resulting in difficulty in differentiating one from the other ([@B87]). Overdose of APAP (≥15 g) has been reported to contribute to the classic intrinsic DILI, including ALF. However, low-dose use of APAP, including daily doses, may lead to idiosyncratic injury and liver adaptation ([@B107]; [@B72]). In a Spanish study evaluating 32 prospectively gathered ALI cases, the APAP-associated Roussel Uclaf Causality Assessment Method (RUCAM) score was higher compared to that of other concomitant medications. The estimated incidence of AALI was 0.4 per million (99% confidence interval \[CI\], 0.2--0.8) in individuals \>15 years of age and 10 per million (95% CI, 4.3--19.4) in APAP users ([@B75]). In addition, APAP-associated idiosyncratic DILI was shown to have immunological manifestations, such as arthralgia, fever, eosinophilia, rash, and thrombocytopenia. Taken together, for rapid and precise detection and/or treatment of APAP-associated idiosyncratic DILI, it is necessary to assess the causality by the RUCAM score.

APAP-Associated Liver Adaptation {#s1_3}
--------------------------------

Liver adaptation to APAP may occur with therapeutic doses in some individuals. APAP overdose could cause ALF, but in several studies, repeated exposure to APAP led to autoprotective effects ([@B29]). A randomized controlled trial identified that the incidence of ALT elevation (\>3 × upper limits of normal) was 31% to 44% in treatment groups receiving APAP ([@B96]). The median maximum ALT was 2.78 (95% CI, 1.47--4.09; P \< 0.001) compared to placebo, suggesting history of APAP ingestion to be considered in differential diagnosis of ALT elevations regardless presence of serum APAP concentrations. Liver adaptation usually presents without clinical symptoms along with relatively low serum liver tests, including ALT that often remain at \<5 × the upper limits of normal. Most of liver adaptations recover ALT levels that gradually drop to normal range, and no clinical decision is required. Therefore, even the serum APAP concentration is negative, a slight increase in liver tests without clinical manifestations or the history of APAP ingestion may refer to the liver adaptation.

Advances in Herbal Therapy for ALI {#s1_4}
----------------------------------

To date, a number of herbal extracts have been identified as effective for prevention of AALI with reasonable evidence in terms of effectiveness and safety ([**Table 1**](#T1){ref-type="table"}). In addition, there are also a number of therapeutic approaches using the natural product extracts after APAP administration with significant amelioration of the liver function and improved survival ([**Table 2**](#T2){ref-type="table"}).

###### 

Effects of bioactive natural product extract pretreatment in ALI.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Herbal                                          Extract dose   APAP dose    Effect/mechanism                                     Ref.
  ----------------------------------------------- -------------- ------------ ---------------------------------------------------- --------------------
  *Acacia catechu* (L.f.) Willd.                  400 mg/kg      750 mg/kg    LPO accumulation↓Antioxidant                         ([@B57])

  *Adansonia digitata* L.                         200 mg/kg      100 mg/kg    ALP, ALT, AST, MDA,SOD↓                              ([@B45])

  *Alnus japonica* (Thunb.) Steud.                200 μg/ml      500 mg/kg    Antioxidant                                          ([@B52])

  *Arctium lappa* L.                              300 mg/kg      800 mg/kg    ALP, ALT, AST, DNA fragmentation↓                    ([@B31])

  *Artemisia absinthium* L.                       500 mg/kg      640 mg/kg    MDME↓                                                ([@B38])

  *Artemisia scoparia* Waldst. & Kitam.           150 mg/kg      640 mg/kg    ALT, AST↓                                            ([@B39])

  *Camellia sinensis* (L.) Kuntze (Green tea)     1000 mg/kg     200mg/kg     ALT, AST, ALP, TB↓                                   ([@B77]; [@B97])

  *Centaurium erythraea* Rafn                     900 mg/kg      750 mg/kg    ALT, AST, LDH↓                                       ([@B64])

  *Cuscuta chinensis* Lam.                        250 mg/kg      835 mg/kg    ALP, ALT, AST, SOD, CAT, MDA↓                        ([@B105])

  *Cuscuta campestris* Yunck.                     250 mg/kg      850 mg/kg    ALT, AST, SOD, CAT, MDA, GPx↓                        ([@B55])

  *Cyperus scariosus* R.Br.                       500 mg/kg      1 g/kg       ALP, ALT, AST↓                                       ([@B40])

  *Genista quadriflora* Munby                     300 mg/kg      1 g/kg       CYP2E1, GSTpi, TNF-α↓                                ([@B11])

  *Glossocardia bidens* (Retz.) Veldkamp          300 mg/kg      500 mg/kg    ALT, AST↓GSH↑                                        ([@B90])

  *Hydrastis canadensis* L.                       1000 mg/kg     400 mg/kg    ALT, AST, Cytochrome P450 2E1↓                       ([@B101])

  *Musanga cecropioides* R.Br. ex Tedlie          500 mg/kg      800 mg/kg    ALT, AST, OTC↓                                       ([@B1])

  *Paeonia × suffruticosa* Andrews                400 mg/kg      400 mg/kg    ALT, GSH, Cytochrome P450 2E1, Hepatic DNA damage↓   ([@B82])

  *Premna tomentosa* Willd.                       750 mg/kg      640 mg/kg    Membrane-bound enzymes↓                              ([@B56])

  *Prosopis farcta* (Banks & Sol.) J.F.Macbr.     75 mg/kg       600 mg/kg    ALT, AST, TG, LDL, VLDL↓                             ([@B10])

  *Pterocarpus erinaceus* Poir.                   75 mg/kg       2 g/kg       ALT, AST, MDA↓GSH↑                                   ([@B5])

  *Sasa veitchii* (Carrière) Rehder               0.2 mL/day     550 mg/kg    ALT, AST, JNK, RIP-1, CYP2E1↓                        ([@B110]; [@B108])

  *Schisandra sphenanthera* Rehder & E.H.Wilson   700 mg/kg      400 mg/kg    ALT, AST, MDA↓                                       ([@B33]; [@B34])

  *Teucrium polium* L.                            250 mg/kg      500mg/kg     ALT, AST, ALP↓                                       ([@B76])

  *Trifolium alexandrinum* L.                     300 mg/kg      1 g/kg       CYP2E1, GSTpi, TNF-α↓                                ([@B36])

  *Tournefortia sarmentosa* Lam.                  500 mg/kg      1000 mg/kg   MDA↓                                                 ([@B86])

  *Zingiber officinale* Roscoe                    0.3 mL/kg\     600 mg/kg\   ALP, ALT, AST, LDH, SDH↓\                            ([@B104])\
                                                  400 mg/kg      3 g/kg       Antioxidant                                          ([@B4])
  -----------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Therapeutic effects of bioactive natural product after APAP overdose.

  Herbal                                        Extract dose   APAP dose    Effect                                              Ref
  --------------------------------------------- -------------- ------------ --------------------------------------------------- ------------------
  *Artemisia absinthium* L.                     500 mg/kg      640 mg/kg    MDME↓                                               ([@B38])
  *Baccharis dracunculifolia* DC.               50 mg/kg       600 mg/kg    ALT, AST, ALP                                       ([@B43])
  *Camellia sinensis* (L.) Kuntze (Green tea)   1000 mg/kg     150 mg/kg    ALP; ALT; GSH; AST, TB↓                             ([@B77]; [@B97])
  *Citrus × aurantium* L.                       1000 mg/kg     300mg/kg     Survival rate                                       ([@B102])
  *Hydrastis canadensis* L.                     1000 mg/kg     400 mg/kg    ALT, AST, Cytochrome P450 2E1↓                      ([@B101])
  *Moringa oleifera* Lam                        400 mg/kg      7 g/kg       GSH, SOD, CAT↓Antioxidant                           ([@B32]; [@B81])
  *Phyllanthus urinaria* L.                     200 mg/kg      550 mg/kg    Cytochrome P450 2E1↓                                ([@B47])
  *Punica granatum* L.                          50 mg/kg       750 mg/kg    ALT, AST↓Antioxidant                                ([@B2])
  *Tournefortia sarmentosa* Lam                 500 mg/kg      1000 mg/kg   ALP, ALT, AST, TNF-α, IL-1β, IL-6, CAT, SOD, GPx↓   ([@B86])
  *Trifolium alexandrinum* L.                   100 mg/kg      100 mg/kg    ALP; ALT, GGTP, TB, MDA↓                            ([@B76])
  *Vitex doniana* Sweet                         400 mg/kg      300 mg/kg    ALP, ALT, AST, GPx↓                                 ([@B3])

*Adansonia digitata* L. {#s1_5}
-----------------------

The methanol extract of *Adansonia digitata L*. (Malvaceae), which is a native tree in Central Africa and commonly known as baobab, fruit pulp (the pulp is dissolved in milk or water to be used as a drink or a sauce for food and is considered one of the popular ingredients in ice products) was also found to exert protective effects against ALI ([@B45]). The protection was mediated through attenuating lipid peroxidation by the scavenging activity of free radicals, as well as the antioxidant activities.

*Alnus japonica* (Thunb.) Steud. {#s1_6}
--------------------------------

Pretreatment with the stem bark of the Betulaceae plant *Alnus japonica* (Thunb.) Steud., a common folk medicine for cancer and hepatitis indigenous to Korea, revealed dose-dependent antioxidant effects in APAP-associated hepatotoxicity ([@B52]). The Alnus species are characterized by high amounts of the triterpenoids and diarylheptanoids compounds; thus, it is suggested that phenolic compounds may be associated with the antioxidant effects ([@B85]).

*Arctium lappa* L. {#s1_7}
------------------

A Saudi Arabian study have confirmed ameliorative effect of *Arctium lappa* L., which has been used as the tea, root extracts against ALI by confirmation on suppressed malondialdehyde content and mitigated most of the hepatic tissue damages caused by APAP overdose in rats, but some necrotic areas, as well as dilated and congested central vein, remained in Artium lappa extract treatment group even 30 days after APAP treatment ([@B31]). It is important to note that there was not full recovery from APAP-associated toxicity a month after the treatment.

*Artemisia scoparia* Waldst. & Kitam. and *Artemisia absinthium* L. {#s1_8}
-------------------------------------------------------------------

In 1993, hydromethanolic extract of *Artemisia scoparia* Waldst. & Kitam. (Compositae) was first reported to protect liver against APAP-induced hepatotoxicity ([@B38]). Pretreatment of the extract (150 mg/kg) could significantly decrease the mortality by reducing serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels when applied APAP at a dose of 1 g/kg, which was a 100% lethal dose in the experiment. In addition, extract from *Artemisia absinthium* L. pretreated with aqueous-methanolic(Compositae) (500 mg/kg) also had the hepatoprotective effects by reducing ALT and AST levels, and inhibiting microsomal drug-metabolizing enzymes ([@B39]).

*Baccharis dracunculifolia* DC. {#s1_9}
-------------------------------

Glycolic extract of *Baccharis dracunculifolia* DC. that contains several chemical compounds, including caffeic acid, p-coumaric acid, cinnamic acid, aromadendrin, isosakuranetin, and artepillin C, was previously reported as the main source of green propolis with potent antioxidant activity that prevents against oxidative mitochondrial damage ([@B43]). The extract of the leaves was testified in APAP-induced hepatotoxicity that revealed high total phenolic and flavonoid contents, which are hepatoprotective properties ([@B73]).

*Brassica juncea* (L.) Czern. and *Angelica keiskei* (Miq.) Koidz. {#s1_10}
------------------------------------------------------------------

*Brassica juncea* (L.) Czern. (Brassicaceae; Indian mustard) is considered to possess diverse pharmacological properties. The mustard seed extract was testified for APAP-induced toxicity in a hepatocellular carcinoma cell line (HepG2) and was found to have protective effects in both post and pretreatment models with a 20 mM APAP dose ([@B70]). Phytochemical analysis showed the presence of vitamin, tannin, flavonoid, and phenolics, and the antioxidant activity revealed a linear correlation with the contents. However, the extent of ROS generation significantly differed that posttreatment inhibited the ROS generation by 58.4%, whereas pretreatment suppressed the generation of ROS by 90.5%. Further experiments confirmed the presence of vitamin E, quercetin, and cetechin, which demonstrated hepatoprotective effect, and the ROS inhibition was confirmed to be associated with antioxidant activities, thus protecting against ALI. An ethanol extract of *Angelica keiskei* (Miq.) Koidz. was also testified in HepG2 and HepaRG cells by culturing with 30 mM APAP ([@B18]). The extract was found to downregulate apoptotic factors, such as caspase-3, -7, and -9, *via* intrinsic and extrinsic pathways to prevent ALI in APAP-induced hepatotoxicity.

*Camellia sinensis* (L.) Kuntze {#s1_11}
-------------------------------

Green tea comes from *Camellia sinensis* (L.) Kuntze. [@B77] tested the effect of green tea extract prior to and 6 h after APAP administration. Independently verified key components of the green tea extract batch GTE50-A0302031114 were polyphenols, catechins, gallates, caffeine, moisture, ash, heavy metals and residues, and these results suggest that green tea extract compounds may downregulate or suppress CYP1A2, 2E1, and 3A4 reduce APAP conversion to the reactive metabolite NAPQI. Interestingly, pretreatment of green tea extract revealed to provide protection against AALI by decreasing APAP covalent binding to protein, thus relatively reducing reactive metabolites for liver injury. However, green tea extract potentiated APAP-induced hepatotoxicity when applied after APAP treatment through causing glutathione depletion, indicating importance of the supplement interactions. Recently, [@B97] found that the natural polyphenol chlorogenic acid is protective against APAP-induced hepatotoxicity through activation of Nrf2 antioxidant signalling pathway by blocking the binding of Nrf2 to Keap1. In addition, ERK1/2 plays a critical role in regulation of the polyphenol chlorogenic acid-derived Nrf2 transcriptional activation. These findings were further supported by a study from the United States that also confirmed increases in serum transaminases and histopathologic scores when administered the green tea extract after APAP ([@B61]).

*Centaurium erythraea* Rafn {#s1_12}
---------------------------

The methanol extract of the leaves from *Centaurium erythraea* Rafn (Gentianaceae; 300 mg/kg per day for 6 days or 900 mg/kg for one day) was found the hepatoprotective effect against APAP-induced hepatotoxicity by reducing the serum concentration of ALT, AST, and lactate dehydrogenase (LDH) in patients ([@B64]).

*Citrus* × *aurantium* L. {#s1_13}
-------------------------

The extract of a citrus fruit (natsumikan; Citrus × aurantium L.) that contains antioxidant nutrients, such as vitamin C and flavonodis, was found effective in improving survival of mice against acute ALI ([@B102]). Administration of 300 mg/kg of APAP led to 100% mortality within 6 h, but 1,000 mg/kg of natsumikan extract and silymarin prolonged survival rates to 33.3% and 50.0%, respectively.

*Cuscuta chinensis* Lam. and *Cuscuta campestris* Yunck. {#s1_14}
--------------------------------------------------------

The dual effects of ethanolic and aqueous extracts of the seeds of *Cuscuta chinensis* Lam. (Convolvulaceae), a traditional Chinese medicine used to nourish the liver and kidney, were noticed in APAP-induced hepatotoxicity ([@B105]). The ethanolic extract prevented the hepatotoxicity induced by APAP and had significant antioxidant activity, but the same dose of aqueous extract showed no hepatoprotective effect, and led to further deterioration of the liver, suggesting importance of the extract types. Moreover, the identified pharmacologically active constituents of the Cuscuta chinensis include polysaccharide, lignans, quinic acid, flavonol, and flavonoids ([@B26]; [@B93]; [@B103]). Additionally, [@B106] testified that the nanoparticle formulation of *Cuscuta chinensis* Lam. was superior to ethanolic extract/aqueous extract in terms of overcoming water-poorly-soluble and the decreasing the treatment dose. Furthermore, the aqueous and methanolic extracts of *Cuscuta campestris* Yunck. (125 and 250 mg/kg), a parasitic plant commonly known as dodder that is used as a folk medicine to treat liver-related diseases, were found to notably exert hepatoprotective and antioxidant effects ([@B55]).

*Cyperus scariosus* R.Br. {#s1_15}
-------------------------

Further examination revealed that *Cyperus scariosus* R.Br. (Cyperaceae) extract (500 mg/kg) had a hepatoprotective effect confirmed by decreased the levels of ALT, AST, and alkaline phosphatase (ALP) in APAP overdose patients/mice ([@B40]).

*Genista quadriflora* Munby and *Teucrium polium* L. {#s1_16}
----------------------------------------------------

Two of the endemic plants (*Genista quadriflora* Munby and *Teucrium polium* L.) in France that are frequently used for dietary and/or medical applications were testified and compared for its hepatoprotective effectiveness against APAP-induced hepatotoxicity in rats ([@B11]). Pretreatments of the rich-polyphenol fractions of them (300 mg/kg per day for 10 days) prior to oral administration of APAP (1 g/kg) exerted a hepatoprotective effect against ALI by improving transaminase leakage and enhancing antioxidant defense. In addition, suppressed miRNA expression of CYP2E1, GSTpi, and TNF-α along with enhanced mitochondrial bioenergetics were suggested to be responsible for the protective effect. It was further suggested that predominant flavonoids and phenolic acids in the extracts may have contributed to the high total polyphenol content.

*Glossocardia bidens* (Retz.) Veldkamp {#s1_17}
--------------------------------------

In BALB/c mice, hot water extracts of *Glossocardia bidens* (Retz.) Veldkamp was found to contain high phenolics (chlorogenic acid and luteolin-7-glucoside). The extracts were effective at protecting against ALI by increasing glutathione levels, reducing the ratio of glutathione to oxidized glutathione in the liver, and inhibiting peroxidation to exert antioxidant ability ([@B90]). In addition, the antioxidant capacity of *Glossocardia bidens* (Retz.) Veldkamp was dependent on the type of the solvents, including hot water, 50% ethanol, and 95% ethanol. It is crucial to note that the capacity was most excellent when applied hot water.

*Hovenia Dulcis* Thunb. {#s1_18}
-----------------------

In China, although *Hovenia Dulcis* Thunb is frequently used to protect the liver against alcoholic injury, its impact against APAP-induced hepatotoxicity remained unclear. [@B25] have confirmed hepatoprotective effects of an ethanol extract of Hovenia Dulcis against ALI in a dose-dependent manner by suppressing cytochrome P450 activity, cell apoptosis, and modulation of bile acid homeostasis imbalance.

*Hydrastis canadensis* L. {#s1_19}
-------------------------

Goldenseal (*Hydrastis canadensis* L.) was further confirmed to be protective against AALI by inhibiting CYP2E1 in rats ([@B101]). Moreover, goldenseal can also inhibit the cytochrome P450 isoforms, including CYP1A2, CYP2D6, CYP2E1, and CYP3A, and the IC~50~ values were 15.7, 7.4, 4.3, and 52.1 µg/ml in rats, respectively.

*Moringa oleifera* Lam. {#s1_20}
-----------------------

[@B32] found that the administration (1 h after APAP) of extract from *Moringa oleifera* Lam. (Moringaceae), an antioxidant with abundant essential minerals, was significantly effective in reducing malondialdehyde and 4-hydroxynonenal protein adduct levels. In addition, the Folin-Ciocalteu assay of the total phenolic compounds revealed that the ethanolic extract of Moringa oleifera has the highest total phenolic content (24.21 ± 1.55 mg gallic acid equivalent/100 g dw followed by leaves, pods, seeds, and stem. Further research confirmed that administration of the extract alleviated the severity of liver injury ([@B81]).

*Musanga cecropioides* R.Br. ex Tedlie and *Vitex doniana* Sweet {#s1_21}
----------------------------------------------------------------

Pretreatment with aqueous extract of the stem bark *Musanga cecropioides* R.Br. ex Tedlie (125--500 mg/kg), which is used as a natural antidote for gastric poisoning in Southwest Nigeria, significantly ameliorated acute elevation of the liver enzymes and hepatotoxicity-associated histopathological lesions within the liver by activating natural antioxidants (flavonoid and alkaloid) ([@B1]). The extract of another local Nigerian remedy (*Vitex doniana* Sweet) for the treatment of liver-related diseases was also assessed in APAP-induced hepatotoxicity ([@B3]). GC-MS profiling on methanolic extract of Vitex doniana fruits indicated 13 different phytoconstituents with β-sitosterol, which was found to have antioxidant and antiradical activities, as the most abundant compound, followed by platycodin D, apigenin, saikosaponinn, and chrysin. The extract significantly attenuated serum liver enzymes and ameliorated the reduction in superoxide dismutase, catalase, glutathione peroxidase and reductase, and 6-phosphate dehydrogenase activities. Furthermore, the increased conjugated dienes, lipid hydroperoxides, and fragmented DNA levels were significantly decreased when administered methanolic extract of *Vitex doniana* Sweet.

*Paeonia* × *suffruticosa* Andrews {#s1_22}
----------------------------------

In the early 21st century, [@B82] explored the impact of cortex of *Paeonia × suffruticosa* Andrews and its underlying mechanisms. Administration of cortex of *Paeonia × suffruticosa* Andrews could prevent liver injury by decreasing ALT, protecting against hepatic glutathione depletion, attenuating cytochrome P450 2E1 activity, and preventing hepatic DNA damage *in vivo*.

*Passiflora subpeltata* Ortega {#s1_23}
------------------------------

According to a study from Brazil, luteolin and quercetin 3-β-d-glucoside were newly detected as compounds in *Passiflora subpeltata* Ortega leaves, and an acetone extract of this plant was found to elevate the serum white blood cell, red blood cell, and hemoglobin counts, and retain the serum biochemical and antioxidant levels to normal range, providing protection against ALI ([@B80]).

*Phyllanthus urinaria* L. {#s1_24}
-------------------------

Oral administration of *Phyllanthus urinaria* L. extract following intraperitoneal administration with a lethal dose of APAP was found to be protective against APAP-induced necrosis by downregulating the cytochrome P450 CYP2E1 protein levels *in vitro* ([@B47]). In addition, a therapeutic dose of *Phyllanthus urinaria* showed no toxicological phenomena in mice.

*Premna tomentosa* Willd. {#s1_25}
-------------------------

Pretreatment with an extract from Indian traditional medicine *Premna tomentosa* Willd. (Lamiaceae) (750 mg/kg for 15 days) before APAP administration (640 mg/kg). It was found that the Indian traditional medicine could prevent the liver injury-induced membrane damage, suggesting the presence of antioxidant compound limonene ([@B23]). In addition, previous preliminary phytochemical screening confirmed the presence of limonene (57.8%) along with other phytoconstituents, including beta-caryophyllene (17.2%), cadalene type sesquiterpene (7.8%), ses quiterpene tertiary alcohol (5.6%), and aditerpene (5.5%) ([@B56]).

*Prosopis farcta* (Banks & Sol.) J.F.Macbr. {#s1_26}
-------------------------------------------

Extract of *Prosopis farcta* (Banks & Sol.) J.F.Macbr. beans were previously found to contain a number of antioxidant phenolic compounds, such as vicenin-2, vitexin, glucoside, and luteolin. In Wister albino rats weighing approximately 200 g, 600 mg/kg of APAP administration significantly increased ALT, AST, cholesterol, and low-density lipoprotein, which were attenuated to near normal ranges when administrated 50 and 75 mg/kg of *Prosopis farcta* (Banks & Sol.) J.F.Macbr. beans. Administration of bean extract prior to APAP resulted in hepatoprotective activity against ALI despite relatively low doses ([@B10]).

*Pterocarpus erinaceus* Poir., Bilberries, and Blackcurrants {#s1_27}
------------------------------------------------------------

Akinmoladun and colleagues explored the hepatoprotective effects of pretreatments of the ethanol stem bark extract and the constituent flavonoid (homopterocarpin) against APAP (2 g/kg). It was found that these substances ameliorated APAP-associated biochemical alterations. Furthermore, higher antioxidant potentials potential was found in homopterocarpin compared to the ethanol stem bark extract, suggesting the importance of the extract types in preventive efficacy against ALI ([@B5]). In addition, an anthocyanin-risk extract from bilberries and black currants was also found to be protective against acute ALI in rats ([@B20]).

*Punica granatum* L. {#s1_28}
--------------------

Surprisingly, 14 days of treatment with *Punica granatum* L. methanolic extract was reported to have very strong effects in ameliorating liver functions after APAP treatment (750 mg/kg) potentially by antioxidant properties that the mean liver ALT and AST levels were even lower in the pomegranate peel posttreatment group after APAP treatment (ALT, 49.6 ± 12.1; AST, 96.1 ± 18.0) compared to the normal saline group without APAP treatment (ALT, 51.5 ± 15.4; AST, 97.9 ± 19.5) ([@B2]).

*Sasa veitchii* (Carrière) Rehder and *Acacia catechu* (L.f.) Willd. {#s1_29}
--------------------------------------------------------------------

In accordance with other extracts from natural products, 7 days of a *Sasa veitchii* (Carrière) Rehder leaf extract (0.2 ml per day) pretreatment significantly decreased hepatic injury markers, including ALT and AST, oxidative stresses, including malondialdehyde and glutathione, histologic damages, inflammatory cytokines, activation of JNK, receptor-interacting protein-1, which has emerged as a key modulator of necrotic cell death, and CYP2E1, whereas the total antioxidant capacity within the liver was increased in an acute APAP mice model (550 mg/kg) ([@B110]; [@B108]). More recently, the seed and bark extracts (400 mg/kg) of *Acacia catechu* (L.f.) Willd. were also found to modulate oxidative stress, antioxidative activities, and liver function to protect against APAP-induced hepatotoxicity in rats with higher potentials in the seed extract for protection of the liver ([@B57]).

*Schisandra sphenanthera* Rehder & E.H.Wilson and *Schisandra chinensis* (Turcz.) Baill. {#s1_30}
----------------------------------------------------------------------------------------

In many regions, *Schisandra sphenanthera* Rehder & E.H.Wilson is widely used to support liver function and is applied in the form of Wuzhi tablet, which is composed of ethanol extracts. Administration of Wuzhi tablet 3 days prior to APAP treatment could significantly alleviate hepatoxicity in a dose-dependent manner along with reduction in the activation of JNK ([@B33]). In addition, potent inhibition of the activities of CYP2E1, CYP3A11, CYP1A2, and KEAP1, and the formation of the oxidized APAP metabolite NAPQI-reduced glutathione, whereas Nrf2 expression was increased. Moreover, pretreatment with Wuzhi tablet suppressed the p53/p21 signalling pathway, which induces cell proliferation proteins that enhance proliferation of hepatocytes. More recently, they compared therapeutic efficacy of Wuzhi tablet to N-acetylcysteine, which is the main antidote for APAP toxicity ([@B34]). When administered Wuzhi tablet 4 h after APAP treatment, it revealed much better therapeutic impact compared to N-acetylcysteine, which were confirmed by morphological, histological, and biochemical evaluations. In addition, Wuzhi tablet additionally stimulated liver regeneration after injury, which were verified by increased expressions of cyclin D1, proliferating cell nuclear antigen, and liver regeneration augmenters. Recently, the extracts of *Schisandra chinensis* (Turcz.) Baill. stems revealed to exert significant amelioration in APAP-induced apoptosis, inflammation, and oxidative stress through regulation of mitogen-activated protein kinase and caspase-3 signaling pathway ([@B60]).

*Tournefortia sarmentosa* Lam. {#s1_31}
------------------------------

APAP induces hepatotoxicity, attenuates lipid peroxidation, and enhances antioxidant enzyme activation, including increases in interleukin (IL)-1β, IL-6, and tumor necrosis factor-α elevated ([@B106]). Pretreatment with the extract of another Chinese herbal medicine, \[*Tournefortia sarmentosa* Lam. (Boraginaceae)\] which is commonly used as an antiinflammatory or detoxicant agent, showed significantly reduced serum concentrations of ALT, AST, ALP, and inflammatory markers ([@B86]).

*Trifolium alexandrinum* L. and *Teucrium polium* L. {#s1_32}
----------------------------------------------------

According to [@B76] compared the APAP group to the APAP plus *Trifolium alexandrinum* L. root extract group, the extract improved ALI in terms of histopathology and DNA fragmentation. Pretreatment of *Teucrium polium* L. (Labiatae) extract was also found to be protective against ALI at doses of 250 and 500 mg/kg as confirmed by histological examinations ([@B36]).

*Zingiber officinale* Roscoe {#s1_33}
----------------------------

Ethanol extract of the rhizome of *Zingiber officinale* Roscoe was effective in ameliorating liver function as confirmed by attenuated serum ALT, AST, ALP, LDH, and succinate dehydrogenase ([@B104]). *Zingiber officinale* Roscoe also prevented APAP-induced acute hepatotoxicity by preventing the decline of liver antioxidant status or on account of the radical scavenging capacity ([@B4]). Because of the crucial involvement of oxidative damage in AALI, antioxidant properties were further tested in AALI.

Future Perspectives and Conclusions {#s2}
===================================

Since the early 1990s, numerous extracts from various natural products have been identified as hepatoprotective at different doses against APAP-induced toxicity by ameliorating oxidative stress and liver enzymes. Despite a large amount of effort and many publications, most studies have testified effects of the extract pretreatment prior to acute APAP administration on serologic, histologic, and morphologic liver-related outcomes *in vivo*, but few studies have explored these effects in hepatic cell lines by culturing with the natural products and administrating APAP. In addition, some of the products contained compounds even more effective than the antidote (NAC) when treated after APAP administration. Few studies have compared these highly effective products, and it is still a challenge to determine the greatest potential products. Therefore, it seems to us that only the number of hepatoprotective products has increased without clinical relativity. Recently, gut microbiota was identified to play a key role in the diurnal variation of APAP-induced hepatotoxicity ([@B42]). Accumulating evidence implicates herbals could treat disease by regulating the gut microbiota ([@B91]; [@B8]; [@B35]). More studies are needed to verify whether the hepatoprotective effect of natural products through this novel mechanism. In addition, further identifications of the following factors may support prevention and treatment of ALI: specific inhibitors of CYPs such as CYP2E1; induction of detoxifying enzymes (UGT, SULT, etc.) that participate in APAP metabolism ([@B94]; [@B15]); treatments to increase or supplement of GSH or NAC to inactivate the reactive metabolite NAPQI rapidly; factors associated with reducing formations of oxidative stress and oxygen free radicals, and protective and preventive factors against mitochondrial damage since mitochondrial dysfunction and damage plays pivotal role in APAP-associated ALI ([@B79]). As is known in China and other Asian countries, herbal medicines have been widely used in clinical settings. In order to ensure the efficacy and repeatability in herbal medicines, the Chinese government has required all manufacturers to formulate strict quality standards for each herb product. Currently, the majority of herbal medicines used in the clinical settings are produced by several large pharmaceutical companies rather than traditional decocting modes. In fact, part of the herbal medicines used for alleviating ALI are granules of a single herb or several herbs, their major constituents have been reported previously. However, herbal therapy for APAP-induced liver injury remains limited in terms of clinical application due to prospective validation by clinical trials. In addition, individual compounds of the herbal extracts are barely studied even in experimental animal models.

The potential hepatotoxicity of herbal products has also been recognized in recent years ([@B83]). Many herbal products have been reported by numerous studies to cause liver injury. The clinical symptoms ranging from acute chronic hepatitis to ALF ([@B37]; [@B111]). Although oxidative stress and necrosis were reported to be related to herbal products toxicities, the underlying mechanism is largely unknown ([@B83]). More studies are needed to explore the mechanism of natural products side effect. Due to their multicomponent nature and multitargeted and synergistic effects, it is extremely challenging to study the specific molecular mechanism of herbal medicine to alleviate APAP-induced liver injury. In future, the researchers may use the information listed in this review as a clue to deeply understand the bioactive compounds in these herbal medicines for alleviating APAP-induced hepatoxicity, and their mechanisms of action. Considering the preventive, protective, and therapeutic effectiveness of the herbal therapies, evaluation of efficacy and safety in clinical trials may also be promising in the future after further confirming effects of each extract type, interactions between the supplements, and synergism between products.
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